A webinar program for oncologists and pathologists
Thursday, Feb. 22, 2018 at 1:00 p.m. CET
Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that may help in selecting the most appropriate chemotherapy regimen for certain high-risk breast cancer patients.
Join Dr. Olaf Wilhelm for a dynamic discussion regarding PITX2 DNA methylation, a biomarker which may help improve therapy decision-making and support physicians in giving patient advice.
Prof. Dr. Olaf G. Wilhelm, MD, Founder and Chief Executive Officer of Therawis Pharma GmbH, Munich
Date: Thurs. Feb 22, 2018
Place: From your desktop
Time: 1:00 p.m. CET
Duration: 1 hour